Aligos Therapeutics, Inc. announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 ? 14, 2023. The clinical (#2900-A) and nonclinical (#2461-C) posters for these data can also be found on the ?Scientific Presentations & Conferences?

section of the Aligos website. The clinical poster describes a Phase 1 study which evaluated 14 oral daily doses of up to 1.0 mg ALG-055009 solution formulation in hypercholesterolemic subjects. Important highlights include: ALG-055009 was well tolerated with no safety signals identified; No clinical evidence of hyper- or hypo-thyroidism was observed; As expected for a thyromimetic, ALG-055009 dose responsively: Increased sex hormone binding globulin levels; Lowered lipids levels; ALG-055009 exposures increased in a dose proportional manner with low variability (geometric CV <30%) and a ~20 hour half-life that supports QD dosing; The planned Phase 2a gelcap formulation delivered exposures ~86% of the solution formulation and did not demonstrate a food effect.

The nonclinical poster describes in vitro and in vivo studies which characterize the properties of ALG-055009. Important highlights include: ALG-055009 is 5-47 times more potent than resmetirom and VK-2809 (parent); ALG-055009 is more beta selective than resmetirom and VK-2809 (parent) in cell based assays; Lipid levels decreased in a dose responsive manner in vivo models; In 13-week repeat dose toxicology studies, ALG-055009 was well tolerated with safety margins supporting dosing in the planned Phase 2a clinical study.